The genomic expression test EndoPredict is a prognostic tool for identifying risk of local recurrence in postmenopausal endocrine receptor-positive, her2neu-negative breast cancer patients randomised within the prospective ABCSG 8 trial

類似資料

• The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2− breast cancer patients
  著者:: Dubsky, P, 等
  出版事項: (2013)
• EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancer
  著者:: Dubsky, P., 等
  出版事項: (2013)
• The predictive impact of body mass index on the efficacy of extended adjuvant endocrine treatment with anastrozole in postmenopausal patients with breast cancer: an analysis of the randomised ABCSG-6a trial
  著者:: Gnant, M, 等
  出版事項: (2013)
• Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone
  著者:: Sestak, Ivana, 等
  出版事項: (2019)
• Efficacy of tamoxifen±aminoglutethimide in normal weight and overweight postmenopausal patients with hormone receptor-positive breast cancer: an analysis of 1509 patients of the ABCSG-06 trial
  著者:: Pfeiler, G, 等
  出版事項: (2013)